Get all the relevant market information you need — get it fast, on time, and accurately with Barchart Plus. FREE 30 Day Trial
or

Petros Pharmaceuticals Inc (PTPI)

Petros Pharmaceuticals Inc (PTPI)
0.0810 x 49 0.0839 x 10
Post-market by (Cboe BZX)
0.0860 -0.0250 (-22.52%) 03/28/25 [NASDAQ]
0.0810 x 49 0.0839 x 10
Post-market 0.0830 -0.0030 (-3.49%) 18:02 ET
Quote Overview for Fri, Mar 28th, 2025
Watch
    Add or delete the symbol from one or more Watchlists.
Day Low
0.0860
Day High
0.0964
Open 0.0917
Previous Close 0.1110 0.1110
Volume 19,116,355 19,116,355
Avg Vol 92,528,719 92,528,719
Stochastic %K 32.12% 32.12%
Weighted Alpha -83.77 -83.77
5-Day Change +0.0130 (+17.81%) +0.0130 (+17.81%)
52-Week Range 0.0542 - 1.4800 0.0542 - 1.4800
  • 1D
  • 5D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
  • MAX
Full Chart
  • OHLC Bars
  • Colored OHLC Bars
  • HLC Bars
  • Candlestick Hollow
  • Candlestick Open-to-Close
  • Candlestick Close-to-Close
  • Heikin-Ashi
  • Line Chart
  • Area Chart
  • Renko
  • Column
  • Baseline
  • Line Break
  • Range
  • Kagi
  • Point And Figure
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,256
  • Shares Outstanding, K 11,319
  • Annual Sales, $ 5,820 K
  • Annual Income, $ -8,160 K
  • EBIT $ -11 M
  • EBITDA $ -7 M
  • 60-Month Beta 2.04
  • Price/Sales 0.17
  • Price/Cash Flow N/A
  • Price/Book N/A
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -5.12
  • Most Recent Earnings $-0.53 on 11/13/24
  • Next Earnings Date 04/07/25 [--]
  • Annual Dividend & Yield N/A (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sector Medical
  • INDUSTRY GROUPING Medical - Drugs

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 1 analysts offering recommendations.
Earnings Estimates - Current Qtr N/A
See More
  • Average Estimate N/A
  • Number of Estimates N/A
  • High Estimate N/A
  • Low Estimate N/A
  • Prior Year N/A
  • Growth Rate Est. (year over year) N/A

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.0542 +58.67%
on 03/25/25
Period Open: 0.0978
0.2300 -62.61%
on 03/26/25
-0.0118 (-12.07%)
since 02/28/25
3-Month
0.0542 +58.67%
on 03/25/25
Period Open: 0.3509
0.6500 -86.77%
on 02/14/25
-0.2649 (-75.49%)
since 12/27/24
52-Week
0.0542 +58.67%
on 03/25/25
Period Open: 1.4800
1.4800 -94.19%
on 04/01/24
-1.3940 (-94.19%)
since 03/28/24

Most Recent Stories

More News
Petros Pharmaceuticals to Partner with Renowned Big Data Provider to Enable Rx-to-OTC Switch Across Multiple Indications

Company to integrate industry leading big data technology solutions into its AI-driven platform to expand capabilities in identifying eligible patients to receive formerly Rx medications over the counter...

PTPI : 0.0860 (-22.52%)
Petros Pharmaceuticals' Proprietary Technology Demonstrates Positive Data in Pivotal Study

Proprietary technology utilizing AI and big data integrations to enable Rx to OTC switch candidates across multiple indications

PTPI : 0.0860 (-22.52%)
Petros Pharmaceuticals Announces Pricing of $9.6 Million Public Offering of Common Stock and Warrants

NEW YORK, NY / ACCESS Newswire / February 18, 2025 / Petros Pharmaceuticals, Inc. (NASDAQ:PTPI) ("Petros" or the "Company"), a company focused on expanding consumer access to medication through over-the-counter...

PTPI : 0.0860 (-22.52%)
Petros Pharmaceuticals Strategically Positioned to Benefit as Technology Leader from Newly Approved FDA OTC Final Rules

Proprietary technology developing quantum computing and applying AI to better enable Rx to OTC switch candidates across multiple indications

PTPI : 0.0860 (-22.52%)
Petros Pharmaceuticals Featured in “New Era of Healthcare, AI, Data and Consumer Empowerment”

Company positions itself for new innovation utilizing AI and quantum computing to help expand patient access to drugs via OTC access

PTPI : 0.0860 (-22.52%)
Proprietary Technology Addressing the Rx-to-OTC Switch Self-Care Market Valued at over $38 Billion annually

Working to identify quantum computing partnerships to strengthen our AI technology to include critical health records to better enable Rx to OTC switch candidates across multiple indications

PTPI : 0.0860 (-22.52%)
The Urvan Group Issues Letter to AMMO Inc. Shareholders Regarding its Nomination of a Full Slate of Highly Qualified Candidates for Election to the Company’s Board of Directors

Steven Urvan (together with the other participants in his solicitation, the “Urvan Group” or “we”), who owns approximately 17.1% of the outstanding common shares of AMMO, Inc. (NASDAQ: POWW) (“AMMO”...

CLAR : 3.83 (-3.53%)
OLN : 24.57 (-2.69%)
SWBI : 9.35 (-1.58%)
VSTO : 44.63 (+0.54%)
MDA.TO : 27.15 (-4.67%)
SPA : 18.51 (+0.11%)
HD : 358.15 (-1.26%)
POWW : 1.3800 (-2.13%)
WRAP : 1.9000 (-4.04%)
PTPI : 0.0860 (-22.52%)
AYRO : 0.5507 (-10.50%)
DD : 74.03 (-2.54%)
Petros Pharmaceuticals Responds to Fraudulent Press Release

NEW YORK, July 28, 2022 (GLOBE NEWSWIRE) -- Petros Pharmaceuticals, Inc. (Nasdaq: PTPI), a leading provider of therapeutics for men’s health, today...

PTPI : 0.0860 (-22.52%)
Petros Pharmaceuticals Kicks Off Social Media Campaign with Celebrity Physician Dr. Drew Pinsky

Dr. Drew to Raise Awareness of Petros Pharmaceuticals’ Mission in The Men’s Health Category and STENDRA® (avanafil)...

PTPI : 0.0860 (-22.52%)
Petros Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Corporate Update

NEW YORK, May 16, 2022 (GLOBE NEWSWIRE) -- Petros Pharmaceuticals, Inc. (“Petros” or “the Company”) (Nasdaq: PTPI), a leading provider of therapeutics...

PTPI : 0.0860 (-22.52%)

Business Summary

Petros Pharmaceuticals Inc. is a men's health company. It engages in identifying, developing, acquiring, and commercializing innovative therapeutics for men's health issues including, endothelial dysfunction, psychosexual and psychosocial ailments, Peyronie's disease, hormone health and substance use...

See More

Key Turning Points

3rd Resistance Point 0.1033
2nd Resistance Point 0.0999
1st Resistance Point 0.0929
Last Price 0.0860
1st Support Level 0.0825
2nd Support Level 0.0791
3rd Support Level 0.0721

See More

52-Week High 1.4800
Fibonacci 61.8% 0.9353
Fibonacci 50% 0.7671
Fibonacci 38.2% 0.5989
Last Price 0.0860
52-Week Low 0.0542

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar
Trading Volatility: How to Use IV Rank & Percentile for Smarter Options Strategies